Iovance Stock Been Hammered: A Buying Opportunity or Lure for Risky Bets
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
Flexibility keeps budgets resilient. Explore techniques to flex categories, set automatic rebalances, and protect core priorities.
18,624 articlesIovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
In 2026, corporate bond spreads tightening is reshaping risk and return for the iShares LQD ETF, as yields, credit qu...
CrowdStrike shares declined about 9% after a fiscal Q1 beat that failed to meet loftier expectations, triggering a br...
SpaceX publicly reframes its business as AI services and infrastructure, a move that could redefine growth prospects ...
After a staggering 453% surge, investors face a crossroads: take profits now or double down on a company reshaping th...
A stronger-than-expected jobs report unleashed a broad market selloff, wiping $1.4 trillion from S&P 500 valuations a...
A dramatic May rally sent applied digital stock skyrocketed as AI optimism surged. This piece breaks down the drivers...
AI-led tech names lead a Nasdaq rebound as volatility subsides and oil prices pull back. Here are the latest numbers,...
As Zepp Health nears the release of its Q1 2026 earnings, investors want clarity on growth, margins, and strategic be...
medicare advantage’s premium comes with a catch that could affect coverage during serious illness. As enrollment tren...
Battery-focused BATT has surged past the SPY, led by a year of strong gains in battery metals and EV supply chains.
When a CFO sells company shares worth millions, investors naturally wonder what it means for stock risk and future re...